AYTU BIOPHARMA, INCAYTUEarnings & Financial Report
Nasdaq
NextMay 14, 2026
AYTU Q2 2026 Key Financial Metrics
Revenue
$15.2M
Gross Profit
$9.6M
Operating Profit
$-2.0M
Net Profit
$-10.6M
Gross Margin
63.5%
Operating Margin
-13.0%
Net Margin
-69.8%
YoY Growth
-6.5%
EPS
$-1.05
Financial Flow
AYTU BIOPHARMA, INC Q2 2026 Financial Summary
AYTU BIOPHARMA, INC reported revenue of $15.2M for Q2 2026, with a net profit of $-10.6M (-69.8% margin). Cost of goods sold was $5.5M, operating expenses totaled $11.6M.
Key Financial Metrics
| Total Revenue | $15.2M |
|---|---|
| Net Profit | $-10.6M |
| Gross Margin | 63.5% |
| Operating Margin | -13.0% |
| Report Period | Q2 2026 |
AYTU BIOPHARMA, INC Annual Revenue by Year
AYTU BIOPHARMA, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $66.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $66.4M |
| 2024 | $81.0M |
| 2023 | $107.4M |
| 2022 | $96.7M |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.0M | $18.0M | $16.6M | $16.2M | $18.5M | $15.1M | $13.9M | $15.2M |
| YoY Growth | -20.9% | -41.5% | -25.0% | -29.3% | 2.6% | -15.8% | -16.2% | -6.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $128.9M | $118.1M | $115.8M | $116.2M | $124.2M | $124.2M | $125.0M | $122.0M |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $30.8M | $27.7M | $29.8M | $30.8M | $34.9M | $19.0M | $23.2M | $14.2M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-254000 | $-788000 | $-1.2M | $2.9M | $-6.5M | $2.8M | $-618000 | $3.7M |